Related Experiment Video
Updated: May 31, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.2K
Integrated Management of Persistent Atrial Fibrillation
Xindi Yue1, Ling Zhou2, Chunxia Zhao2
1Division of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
Biomedicines
|January 25, 2025
Summary
Atrial fibrillation (AF) incidence is increasing globally. This review details optimized treatments for persistent AF, focusing on rhythm control, rate control, and risk factor management to improve patient outcomes.
Area of Science:
- Cardiology
- Electrophysiology
- Internal Medicine
Background:
- Global incidence of atrial fibrillation (AF) is rising.
- AF increases risks of heart failure, stroke, and mortality.
- Effective management requires rhythm/rate control, risk factor reduction, and stroke prevention.
Purpose of the Study:
- To review the current state of persistent atrial fibrillation (AF) treatment.
- To highlight optimized strategies for rhythm control, rate control, and risk factor management.
- To discuss advancements in catheter ablation techniques for persistent AF.
Main Methods:
- Literature review of current treatments for persistent atrial fibrillation.
- Analysis of catheter ablation and adjunctive techniques.
- Synthesis of data on rhythm control, rate control, and risk factor management.
Main Results:
- Catheter ablation is a primary rhythm control strategy for AF.
- Limited success rates of catheter ablation, especially for persistent AF, necessitate further research.
- Investigational adjunctive ablation techniques aim to improve efficacy.
Conclusions:
- Optimized treatments are crucial for managing persistent atrial fibrillation.
- Integrated approaches to rhythm control, rate control, and risk factor management are essential.
- Ongoing research into advanced ablation techniques holds promise for improved AF management.
Related Concept Videos
01:30Pulse rhythm
754
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
754
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:28Disturbances in Heart Rhythm
886
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
886
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
146
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
146
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
894
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
894